European Primary Care Cardiovascular Society

Lipids

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD

A discussion on CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - June 20, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Key findings of CV outcomes trials with icosapent ethyl

10' education - May 18, 2022 - Prof. Wouter Jukema, MD, PhD

Triglyceride-rich lipoproteins as residual CV risk in patients on statins

10' education - May 8, 2022 - Prof. Alberto Zambon, MD, PhD

Treating elevated Lp(a): beginning of an era

3' education - Apr. 16, 2022 - Steven Nissen, MD

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

New cholesterol guidelines: aim therapy at patients at highest risk who will benefit most

3' education - Nov. 22, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Lipids and food

10' education - July 11, 2018 - Prof. David Marais - Cape Town, South Africa

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

PCSK9 inhibitor has very good benefit-to-risk profile in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg - Paris, France

How do the latest guideline changes affect management of dyslipidaemia in primary care?

10' education - May 26, 2017

What is the evidence base for lipid modification in the guidelines updates?

10' education - Feb. 24, 2016 - Prague - EPCCS 2015

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels
##SCROLLER_ITEMS_FULL_TITLE##

Cholesterol guideline breaking news in USA

3' education - Dec. 16, 2013 - AHA 2013 - Clyde Yancy

Improved use of high-intensity statin with centrally controlled individualized reminders

News - Mar. 14, 2023

ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.

LDL-c lowering with new oral PCSK9 inhibitor in hypercholesterolemia

News - Mar. 14, 2023

ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.

Reduction of CV events with bempedoic acid in statin-intolerant patients

News - Mar. 14, 2023

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

Lp(a) levels in children with popable FH and definite FH

Literature - Dec. 6, 2022 - De Boer LM, et al. - Eur Heart J. 2022

A Dutch cross-sectional study showed that Lp(a) levels were higher and more often elevated in children with a clinical presentation of FH in whom no FH-causing mutation was detected compared with children with a mutation and their unaffected siblings.

Efficacy and safety of PCSK9 siRNA in primary prevention

Literature - Nov. 23, 2022 - Ray KK, et al. - Eur Heart J. 2022

In an ORION-11 substudy, inclisiran reduced LDL-c, non-HDL-c and apoB levels in a subgroup of high-risk patients with elevated LDL-c but without prior CV events receiving maximally tolerated statin therapy.

Effect of dietary supplements on cholesterol compared with low-dose statin and placebo

News - Nov. 7, 2022

AHA 2022 In individuals with an increased 10-year ASCVD risk, rosuvastatin 5 mg daily reduced LDL-c, TC, and TG more than fish oil, cinnamon, garlic, turmeric, plant sterols, red yeast rice, or placebo. Moreover, no supplements reduced LDL-c significantly compared with placebo.

Does low-frequency intermittent fasting reduce LDL-c?

Literature - Oct. 31, 2022 - Bartholomew CL et al. - Eur Heart J Open. 2021

In an RCT with 71 participants, low-frequency intermittent fasting for 26 weeks did not alter LDL-c levels compared with an ad libitum diet. However, it did lower insulin resistance and the metabolic syndrome score.

Long-term treatment with PCSK9 is safe and reduces LDL-c in in pediatric HeFH patients

Literature - Oct. 7, 2022 - Santos RD, et al. - Lancet Diabetes Endocrinol. 2022

The HAUSER-RCT study showed that in pediatric patients with HeFH, treatment with evolocumab for 24 weeks is safe and reduces LDL-c levels, compared with placebo. But what about the long-term safety and efficacy of evolocumab in this patient population?

Reduced statin eligibility in low-ASCVD-risk European countries by 2021 ESC Guidelines

Literature - Oct. 4, 2022 - Mortensen MB, et al. - JAMA Cardiol. 2022

In a population-based cohort study, the clinical performance of the 2021 ESC Guidelines for CVD prevention on eligibility of primary prevention with statins was compared with that of the 2019 ESC/EAS, 2016 NICE, and 2013 ACC/AHA guidelines.

What are the real effects of statins on muscle symptoms?

3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD
‘There is a lot of misinformation about how dangerous statins are’ says Prof. Baigent. This analysis showed that there is a small excess of muscle symptoms in the first year after starting statin therapy, but no excess in risk thereafter.

ESC 2022 ‘There is a lot of misinformation about how dangerous statins are’ says Prof. Baigent. This analysis showed that there is a small excess of muscle symptoms in the first year after starting statin therapy, but no excess in risk thereafter.

Early and long-term PCSK9 inhibitor use associated with continued CV benefit

News - Aug. 30, 2022

ESC 2022 In the open-label extension of the FOURIER trial, evolocumab maintained LDL-c reduction. Moreover, early treatment initiation was associated with sustained accumulation of CV benefit, including CV death.

Majority of reported cases of muscle symptoms are not attributable to statins

News - Aug. 29, 2022

ESC 2022 The researchers of this meta-analysis aimed to provide reliable information about the effects of statins on muscle adverse events from double-blind, randomized trials.